Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of +17.24% and +5.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?